Telix Pharmaceuticals Limited (ASX:TLX)
14.53
+0.87 (6.37%)
Sep 19, 2025, 4:14 PM AEST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M USD in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
4.85
Revenue / Employee
$2.84M
Employees
234
Market Cap
4.92B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Ansell | 3.06B |
Mesoblast | 26.23M |
Regis Healthcare | 1.16B |
Telix Pharmaceuticals News
- 11 hours ago - TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 1 day ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman - GlobeNewsWire
- 4 days ago - TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 5 days ago - Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX - PRNewsWire
- 5 days ago - TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 9 days ago - TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 9 days ago - TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewsWire
- 9 days ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman - GlobeNewsWire